Text Size:AAA

人々 CD70/CD27L/TNFSF7  タンパク質

All CD70 Reagents

製品の説明: Active  
発現宿主: Human Cells  
50 µg 
5 µg 
100 µg 
Add to Cart
  • Slide 1

Browse CD70/CD27L/TNFSF7 Products by

CD70/CD27L/TNFSF7 Related Area

CD70/CD27L/TNFSF7 関連経路

CD70/CD27L/TNFSF7 関連製品

CD70/CD27L/TNFSF7 関連製品

Featured Reagent Products

CD70/CD27L/TNFSF7 サマリー & タンパク質情報

CD70/CD27L/TNFSF7 関連情報

CD70/CD27L/TNFSF7 背景

遺伝子の概要: The protein encoded by CD70 gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF27/CD27. It is a surface antigen on activated, but not on resting, T and B lymphocytes. It induces proliferation of costimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. This cytokine is also reported to play a role in regulating B-cell activation, cytotoxic function of natural killer cells, and immunoglobulin sythesis. [provided by RefSeq, Jul 2008]
General information above from NCBI
サブユニット構造: Homotrimer. {ECO:0000305}.
細胞内位置: Membrane; Single-pass type II membrane protein.
シーケンスの類似性: Belongs to the tumor necrosis factor family. {ECO:0000305}.
General information above from UniProt

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.

Immune Checkpoint
Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

CD70/CD27L/TNFSF7 代替名

CD27LG,Cd27l,Tnfsf7, []
CD27L,CD27LG,TNFSF7, [homo-sapiens]
CD27L,CD27LG,CD70,TNFSF7, [human]
Cd27l,CD27LG,Tnfsf7, [mus-musculus]

CD70/CD27L/TNFSF7 関連研究

  • Adam PJ, et al. (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer. 95(3): 298-306.
  • Keller AM, et al. (2007) Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc Natl Acad Sci U S A. 104(14): 5989-94.
  • Grewal IS. (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 12(3): 341-51.
  • Boursalian TE, et al. (2009) Targeting CD70 for human therapeutic use. Adv Exp Med Biol. 647: 108-19.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"